Clarithromycin detailed information
 | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 50% |
| Protein binding | low binding |
| Metabolism | hepatic |
| Elimination half-life | 3-4 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C38H69NO13 |
| Molar mass | 747.953 g/mol |
Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydia pneumoniae or TWAR), skin and skin structure infections, and, in HIV and AIDS patients to prevent, and to treat, disseminated Mycobacterium avium complex (MAC). In addition, it is sometimes used to treat Legionellosis Clarithromycin is available under several brand names, for example Biaxin, Klaricid, Claripen and Claridar.
History
Clarithromycin was invented by scientists at the Japanese drug company Taisho Pharmaceutical in the 1970s. The product emerged through efforts to develop a version of the antibiotic erythromycin that did not experience acid instability in the digestive tract and thereby cause side effects, such as nausea and stomach ache. Taisho filed for patent protection over its new drug around 1980 and subsequently introduced a branded version of its drug, called Clarith, to the Japanese market in 1991. In 1985 Taisho had partnered with the American company Abbott Laboratories for the international rights, and Abbott also gained FDA approval for Biaxin in October 1991. The drug went generic in Europe in 2004 and in the U.S. in mid-2005.
Potential new uses
The Australian biotechnology company Giaconda is working on a new triple drug therapy for Crohn's disease that combines clarithromycin with rifabutin and clofazimine.
Available forms
Clarithromycin is commonly administered in tablets (Biaxin), extended-release tablets (Biaxin XL), or oral suspension. In the United States generic clarithromycin is available from Andrx, Genpharm, Ivax, Ranbaxy Laboratories, Roxane, Sandoz, Teva and Wockhardt. It is also used as part of a combination therapy to treat Helicobacter pylori. In the Middle East it is available as Claridar, produced by Dar Al Dawa.
Mechanism of action
Clarithromycin prevents bacteria from growing, by interfering with their protein synthesis. Clarithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Clarithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila. Besides this bacteriostatic effect, clarithromycin also has bactericidal effect on certain strains such as Haemophilus influenzae, Streptococcus pneumoniae and Neisseria gonorrhoeae.
Pharmacokinetics
Unlike erythromycin, clarithromycin is acid-stable and can therefore be taken orally without being protected from gastric acids. It is readily absorbed, and diffused into most tissues and phagocytes. Due to the high concentration in phagocytes, clarithromycin is actively transported to the site of infection. During active phagocytosis, large concentrations of clarithromycin is released. The concentration of clarithromycin in the tissues can be over 10 times higher than in plasma. Highest concentrations were found in liver and lung tissue.
Metabolism
Clarithromycin has a fairly rapid first-pass hepatic metabolism, that is, it is metabolised by the liver. However, this metabolite, 14-hydroxy clarithromycin is almost twice as active as clarithromycin. The half-life of clarithromycin is about 5 hours and 14-hydroxy clarithromycin's about 7 hours. Clarithromycin's and its metabolites' main routes of elimination are urinary and biliary excretion.
Side effects
Most common side-effects are gastrointestinal: diarrhea, nausea, abdominal pain and vomiting, facial swelling. Less common side-effects include headaches, dizziness/motion sickness, rashes, alteration in senses of smell and taste, including a metallic taste that lasts the entire time one takes it. Dry mouth, anxiety, hallucinations, and nightmares have also been reported. In more serious cases it has been known to cause anaphylactic shock, jaundice, other liver disorders, and kidney problems including kidney failure. Inform your doctor immediately if side effects are extremely bothersome or serious. Clarithromycin may cause false positives on urine drug screens for cocaine.
Special precautions
Allergic reactions can occur with clarithromycin use. People with a history of allergy, asthma, hay fever or hives seem to be more susceptible to these reactions, and it is normally recommended they avoid the use of Clarithromycin. The reaction can be immediate and severe.
Allergic symptoms include wheezing, hives, itching, swelling, spasms in the throat and breathing tubes, swelling of the face and neck, joint and muscle pain, difficulty breathing, fever and skin rashes. Rashes can range in severity, the most serious cases being toxic epidermal necrolysisand Stevens-Johnson syndrome. Nausea and vomiting are not symptoms of an allergic reaction.
Resistance
Many Gram positive microbes quickly develop resistance to clarithromycin after standard courses of treatment, most frequently via acquisition of the erm(B) gene, which confers high-level resistance to all macrolides.[1]
Contraindications
Clarithromycin should be used with caution if the patient has liver or kidney disease, certain heart problems (e.g., QT prolongation or bradycardia), or an electrolyte imbalance (e.g., low potassium or magnesium levels). Many other drugs can interact with clarithromycin, which is why the doctor should be informed of any other drugs the patient is taking concomitantly. Clarithromycin is almost never used in HIV patients due to significant interaction with HIV drugs.
References
- ↑ Malhotra-Kumar S, Lammens C, Coenen S; et al. (2007). "Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebo-controlled study". Lancet. 369: 482&ndash, 90. doi:10.1016/S0140-6736(07)60235-9. PMID 17292768.
External links
- Biaxin Official web site by Abbott Laboratories
- U.S. Patent 4,331,803
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Macrolide antibiotics